Prof. Liang is mainly engaged in the research on drug design, medicinal chemistry, chemical biology, molecular pharmacology, and drug development for the treatment of inflammation, cancer, and inflammation-mediated cardiovascular diseases. He won many honors in the past 5 years, including Expert of “The Recruitment Program of Global Experts of Zhejiang Province” (known as “the Thousand Talents Plan, Zhejiang Province”, 2012); Zhejiang Provincial High-Level Innovative Health Talents, 2010-2015; Wenzhou municipal “580” talent (Wenzhou Distinguished Expert); Member of American Society of Biochemistry and Molecular Biology, Chinese Pharmacological Society and Chinese Pharmaceutical Association.
Meanwhile, he has been sponsored by a number of research fundings in the past 5 years, including 3 grants from National Natural Science Foundation of China. Up to now, more than 80 peer-reviewed papers have been published on high quality journal, such as Diabetes, Oncotarget, TiPS, CGFR, JMC, JCMM, BJP, IJC, and Plos One etc., accumulating more than 800 citations. His work has been well recognized and awarded by both provincial and city government (2nd Award in Science and Technology, Zhejiang Province Department of Education, 2010; 1st Award in Science and Technology, Wenzhou City Government, 2011; 3rd Award in Science and Technology, Zhejiang Province, 2011). In addition, he has obtained 8 authorized Chinese patents in the field of new drug development. Also, he is the invited reviewer for J Med Chem/Brit J Pharmacol/Bioorg Med Chem, guest editor of Current Pharmaceutical Design, Editorial Board Member of Endoplasmic Reticulum Stress in Cancers. Four compounds discovered in his center have demonstrated promising pharmacological application and low toxicity, and now are under the pre-clinical evaluation as anti-inflammatory or anti-cancer candidates.